Paul Tudor Jones’s Dermata Therapeutics DRMA Stock Holding History

Paul Tudor Jones’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4	Closed	-$4K	–	2536
2022 Q4	$4K	Hold	4	–	–	﹤0.01%	2290
2022 Q3	$5K	Hold	4	–	–	﹤0.01%	2243
2022 Q2	$7K	Hold	4	–	–	﹤0.01%	2036
2022 Q1	$13K	Hold	4	–	–	﹤0.01%	1909
2021 Q4	$18K	Buy	+4	New	+$35.4K	﹤0.01%	2294

Other funds holding DRMA

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Paul Tudor Jones's DRMA Position: Q1 2023 in Review

Paul Tudor Jones sold out of Dermata Therapeutics (DRMA) in Q1 2023, closing a stake of 4 shares — an estimated $4K sold.

Paul Tudor Jones first reported a position in DRMA in Q4 2021 and held it in 5 quarters. The position peaked at $18K in Q4 2021. 4 funds tracked by Wall St. Rank hold DRMA as of Q1 2023.

Paul Tudor Jones reported no remaining Dermata Therapeutics position as of Q1 2023 after selling out during the quarter.
Paul Tudor Jones sold 4 Dermata Therapeutics shares in Q1 2023, an estimated $4K.
Paul Tudor Jones first reported a position in Dermata Therapeutics in Q4 2021 and held it in 5 quarters.
Paul Tudor Jones's Dermata Therapeutics position peaked at $18K in Q4 2021.
4 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2023.

Based on Tudor Investment Corp's 13F filing for Q1 2023, filed 15 May 2023.